Search Results

November 2021 "Cambridge’s Japanese-owned life sciences company Sosei Heptares has clinched a lucrative

Among those hitching their wagons to that star are Verily and Sosei Heptares, which have struck a research The financial details of the strategic collaboration weren’t released, but Sosei Heptares’ past two team-ups

December 2021 "Tokyo, Japan and Cambridge, UK, 24 December 2021 – Sosei Group Corporation (“Sosei Heptares the HSR Act, under the terms of the License Agreement Neurocrine Biosciences has agreed to pay Sosei Heptares

Chris Tate co-founded Heptares after reading one paper on a Friday afternoon. He co-founded Heptares (now Sosei Heptares) in 2007, a company that has since produced over 250 GPCR That stability was what made crystallization tractable and what became the foundation of Heptares. Join me to learn more about Chris’s work and his role in founding Heptares which was later acquired by Sosei and became Sosei Heptares .

Prior to these roles this he was Head of Pharmacology at Heptares Therapeutics Ltd., a UK-based biotechnology These successes enabled the US$400M sale of Heptares Therapeutics Ltd. to the Sosei Group Corporation Prior to joining Heptares, Chris was a neuroscience researcher at GlaxoSmithKline, UK (1998-2009).

Chris Tate's thermostabilization strategy finally made GPCR structures routine, the insight that seeded Heptares She co-founded Heptares Therapeutics and served as Chief Scientific Officer for twelve years, through β-adrenergic signaling set a career in motion 07:07 A venture capital visit to the LMB and the founding of Heptares As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery